The Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE's New Methods Manual.

Health Technology Assessment (HTA) NHS England National Institute for Health and Care Excellence (NICE) economic evaluation methods development technology evaluation

Journal

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
ISSN: 1524-4733
Titre abrégé: Value Health
Pays: United States
ID NLM: 100883818

Informations de publication

Date de publication:
10 2023
Historique:
received: 22 09 2022
revised: 04 05 2023
accepted: 23 05 2023
medline: 25 9 2023
pubmed: 3 6 2023
entrez: 2 6 2023
Statut: ppublish

Résumé

The National Institute for Health and Care Excellence (NICE) recently completed a review of its methods for health technology assessment, involving a 2-stage public consultation. We appraise proposed methodological changes and analyze key decisions. We categorize all changes proposed in the first consultation as "critical," "moderate" or "limited" updates, considering the importance of the topic and the degree of change or the level of reinforcement. Proposals were followed through the review process, for their inclusion, exclusion, or amendment in the second consultation and the new manual. The end-of-life value modifier was replaced with a new "disease severity" modifier and other potential modifiers were rejected. The usefulness of a comprehensive evidence base was emphasized, clarifying when nonrandomized studies can be used, with further guidance on "real-world" evidence developed separately. A greater degree of uncertainty was accepted in circumstances when evidence generation raised challenges, in particular for children, rare diseases, and innovative technologies. For some topics, such as health inequality, discounting, unrelated healthcare costs, and value of information, significant changes were possibly warranted, but NICE decided not to make any revisions at present. Most of the changes to NICE's health technology assessment methods are appropriate and modest in impact. Nevertheless, some decisions were not well justified and further research is needed on several topics, including investigation of societal preferences. Ultimately, NICE's role of protecting National Health Services resources for valuable interventions that can contribute toward improving overall population health must be safeguarded, without accepting weaker evidence.

Identifiants

pubmed: 37268059
pii: S1098-3015(23)02617-7
doi: 10.1016/j.jval.2023.05.015
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1503-1509

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Auteurs

Aris Angelis (A)

Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, England, UK; Department of Health Policy and LSE Health, London School of Economics and Political Science, London, England, UK. Electronic address: aris.angelis@lshtm.ac.uk.

Martin Harker (M)

Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, England, UK.

John Cairns (J)

Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, England, UK.

Mikyung Kelly Seo (MK)

Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, England, UK; Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; Department of Surgery and Cancer, Imperial College London, London, England, UK.

Rosa Legood (R)

Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, England, UK.

Alec Miners (A)

Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, England, UK.

Virginia Wiseman (V)

Department of Global Health and Development, London School of Hygiene & Tropical Medicine, London, England, UK.

Kalipso Chalkidou (K)

School of Public Health, Imperial College London, London, England, UK.

Richard Grieve (R)

Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, England, UK.

Andrew Briggs (A)

Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, England, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH